ASSESSMENT OF PERIODONTAL TISSUE CONDITION IN PATIENTS WITH PERI-IMPLANTITIS AGAINST THE BACKGROUND OF THE TREATMENT AND PREVENTION COMPLEX

Abstract

Peri-implantitis is a frequent complication of dental implantation, characterised by chronic inflammation and progressive destruction of bone surrounding the implant. Optimising treatment strategies for this condition remains a major challenge in contemporary dentistry.Aim of the study was to evaluate periodontal indices in patients with peri-implantitis during administration of a therapeutic-preventive complex (TPC). Materials and methods. Sixty-seven patients aged 25–55 years with peri- implantitis against the background of chronic generalised periodontitis and atherosclerosis were examined. Twogroups were formed: a comparison group (n = 28) that received standard protocol therapy only, and a main group (n = 39) that, in addition to standard therapy, received a formulated TPC comprising antioxidant, anti- inflammatory, probiotic (to restore microbiocenosis), microcirculatory and osteotropic agents. The TPC was repeated 6 months after treatment onset. Periodontal status was assessed using the PMA index (%) and the gingival bleeding index (Mühlemann & Son). Data were analysed by variation statistics with Student’s t-test; p < 0.01 was considered significant. Results. At baseline both groups exhibited pronounced periodontal inflammation: mean PMA > 50 % (moderate gingivitis) and bleeding index > 1.3 units, confirming active gingival inflammation. After 12 months, changes in the comparison group were minimal and statistically insignificant (PMA 52–60 %, bleeding index 1.41–1.45). In contrast, the main group demonstrated rapid and sustained improvement following TPC administration: after 3 months PMA decreased from 54.46 ± 5.22 % to 25.31 ± 2.34 %, and bleeding index from 1.63 ± 0.15 to 1.22 ± 0.11. By month 6 the lowest values were recorded (PMA 22.14 ± 2.09 %; bleeding index 1.17 ± 0.10). At 12 months PMA rose slightly to 31.65 ± 3.18 %, yet remained significantly below baseline and almost half that of the comparison group; the bleeding index was 1.29 ± 0.12 versus 1.45 ± 0.15.Conclusions. Incorporation of the proposed TPC into standard peri-implantitis therapy markedly reduces inflammatory response in peri-implant tissues and sustains the therapeutic effect over one year, far surpassing the efficacy of standard treatment alone. These findings support the feasibility of comprehensive anti-inflammatory and osteoprotective therapy to prevent peri-implantitis progression and preserve peri-implant tissues.